Glaucoma News and Research

Latest Glaucoma News and Research

Sunridge International to present patented, 2-minute, non-invasive PNT treatment at SWIA Conference

Sunridge International, said it will be presenting details of its patented pneumatic trabeculoplasty treatment a non-invasive treatment at the upcoming Southwest Investment Association, Inc. Conference on March 13, 2010, at the Westin Stonebriar Hotel in Frisco, Texas.

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.

8 Mar 2010

World through the eyes of a person with eye disease

Lighthouse International, the non-profit leader in vision healthcare, research, education and advocacy, launches a new website that features the first customizable, low-vision simulator that shows how a person with an eye disease sees the world. Visitors can choose a video from YouTube and select a filter that simulates retinitis pigmentosa, macular degeneration, glaucoma or diabetic retinopathy.

6 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Sunridge International, announced today that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China.

3 Mar 2010

University of Michigan Health System opens new facility for eye care, diabetes research

On March 1, the first eye patients will enter an innovative new $132 million facility that expands the University of Michigan Health System's capacity for eye care, research and education, and unites diabetes researchers as they work to accelerate the search for a cure and prevention of diabetes.

27 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

Study: Elderly people with untreated visual disorders more likely to develop Alzheimer's disease

Elderly people with visual disorders that are left untreated are significantly more likely to develop Alzheimer's disease -- the most common form of dementia, according to a University of Michigan Health System study.

19 Feb 2010

Report: Green tea catechins may protect against glaucoma and other common eye diseases

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

19 Feb 2010

Alcon reports 2009 fourth quarter results

Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.

11 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Glaucoma medications appear to reduce mortality risk

Glaucoma patients who take medication for the condition appear to have a reduced likelihood of death, according to a report in the February issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

9 Feb 2010

Sunridge International extends distribution contract with Beijing Vision World Trading

Sunridge International announced today that they have extended the exclusive distribution agreement with Beijing Vision World Trading Co., Ltd. for an additional 4 years.

6 Feb 2010

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

Low Vision of Michigan introduces new device for RP patients

To commemorate Low Vision Awareness Month this February, Dr. Sheldon Smith, optometrist at Low Vision of Michigan, P.C., is offering free evaluations to patients diagnosed with retinitis pigmentosa (RP), a leading cause of low vision, in hopes that they might be candidates for a brand-new device designed to enhance or restore sight.

4 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

Unusual molecule in brain and retina can trigger vision loss

Scientists have identified a double agent in the eye that, once triggered, can morph from neuron protector to neuron killer. The discovery has significant health implications since the neurons killed through this process results in vision loss and blindness.

2 Feb 2010

Health News Digest features Sunridge International's patented 'PNT' procedure

Sunridge International's patented "PNT" procedure was the topic of discussion in one of Health News Digest's recent articles published on January 24, 2010.

27 Jan 2010

Glaucoma News and Research

Latest Glaucoma News and Research

Sunridge International to present patented, 2-minute, non-invasive PNT treatment at SWIA Conference

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

World through the eyes of a person with eye disease

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

University of Michigan Health System opens new facility for eye care, diabetes research

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Study: Elderly people with untreated visual disorders more likely to develop Alzheimer's disease

Report: Green tea catechins may protect against glaucoma and other common eye diseases

Alcon reports 2009 fourth quarter results

Study shows more women die of heart disease each year than men

Glaucoma medications appear to reduce mortality risk

Sunridge International extends distribution contract with Beijing Vision World Trading

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Low Vision of Michigan introduces new device for RP patients

Study shows Cymbalta reduces chronic low back pain

Unusual molecule in brain and retina can trigger vision loss

Health News Digest features Sunridge International's patented 'PNT' procedure

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Glaucoma News and Research

Latest Glaucoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in